We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Clinical Updates

Accelerating Depression Recovery: The Impact of Measurement-Based Care in Pakistan’s Low-Resource Settings

MedXY Editorial Team•Oct 7, 2025•Clinical Updates
Low- and Middle-Income Countriesmajor depressive disorder

Highlight

Measurement-Based Care (MBC) leads to a significantly faster time to response and remission compared to standard care in adults with major depressive disorder (MDD) in Pakistan.

MBC integrates structured symptom and side-effect monitoring to inform antidepressant dose adjustments, using limited pharmacotherapy options (paroxetine or mirtazapine).

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Bridging the Gap: Gender Disparities in Critical Care Authorship Across Economic ContextsThis bibliometric study reveals persistent gender disparities in authorship of critical care publications, with women better represented in low- and middle-income countries and a modest increase in female authorship from 2018 to 2022 globalAug 25, 2026Navigating Conflicting Clinical Trial Evidence: The FDA’s Approval Journey of Gepirone Extended Release for Major DepressionThis article critically examines the FDA’s approval of gepirone ER for major depressive disorder despite multiple negative trials, highlighting regulatory flexibility, statistical and clinical considerations, and implications for tranAug 11, 2026Semaglutide Reduced Effort Discounting and Improved Motivation Signals in Major Depressive DisorderIn a 16-week randomized trial, adjunctive oral semaglutide improved effort-based decision-making in adults with major depressive disorder and overweight or obesity, suggesting a potential role for GLP-1 receptor agonism in reward-related dyMay 5, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Synergistic Neuromodulation: Combined rTMS and tDCS Outperform Monotherapy in Patients with Anxious Depression
A double-blind RCT involving 240 patients reveals that combining rTMS and tDCS significantly improves remission rates and symptom reduction in Major Depressive Disorder with comorbid anxiety compared to single-modality or sham treatments, p
Feb 23, 2026
Rest-Activity Rhythms as Digital Biomarkers: Predicting Relapse in Major Depressive Disorder via ActigraphyA landmark one-year actigraphy study reveals that sleep phase variability and daily activity amplitude are significant objective markers for predicting MDD relapse, offering a scalable path toward personalized, preventive psychiatric care.Feb 21, 2026
Decoding Antidepressant Response: Genetic and Phenotypic Markers of Treatment Complexity and Sustained UseA large-scale retrospective cohort study identifies specific phenotypic traits and genetic markers, including the SLAMF3/LY9 locus, that predict antidepressant treatment complexity and sustained use, offering a roadmap for precision psychiaJan 31, 2026